Comparison of total body irradiation (TBI) and Non-TBI conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with peripheral T cell lymphoma: a multicenter retrospective study in China.

IF 2.4 3区 医学 Q2 HEMATOLOGY
Annals of Hematology Pub Date : 2025-06-01 Epub Date: 2025-06-07 DOI:10.1007/s00277-025-06407-w
Hongye Gao, Jiali Wang, Zhuoxin Zhang, Yannan Jia, Wenbin Cao, Yawei Zheng, Xiaolei Pei, Weihua Zhai, Rongli Zhang, Xin Chen, Qiaoling Ma, Jialin Wei, Donglin Yang, Aiming Pang, Yi He, Sizhou Feng, Hao Zhang, Xin Du, Yao Liu, Dehui Zou, Xianmin Song, Erlie Jiang
{"title":"Comparison of total body irradiation (TBI) and Non-TBI conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with peripheral T cell lymphoma: a multicenter retrospective study in China.","authors":"Hongye Gao, Jiali Wang, Zhuoxin Zhang, Yannan Jia, Wenbin Cao, Yawei Zheng, Xiaolei Pei, Weihua Zhai, Rongli Zhang, Xin Chen, Qiaoling Ma, Jialin Wei, Donglin Yang, Aiming Pang, Yi He, Sizhou Feng, Hao Zhang, Xin Du, Yao Liu, Dehui Zou, Xianmin Song, Erlie Jiang","doi":"10.1007/s00277-025-06407-w","DOIUrl":null,"url":null,"abstract":"<p><p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a potentially curative treatment for peripheral T-cell lymphoma (PTCL), but the optimal conditioning regimen, particularly the use of total body irradiation (TBI), remains debated. To address this, we investigated outcomes from a cohort of 408 PTCL patients who underwent HSCT across five qualified medical centers in China. Focusing on a subset of 50 patients who received myeloablative conditioning prior to allo-HSCT, we compared outcomes between TBI-based (n = 28) and busulfan-based non-TBI (n = 22) regimens. Our analysis revealed comparable engraftment kinetics, incidence of acute and chronic graft-versus-host disease (GVHD), and overall survival (OS) between the TBI and non-TBI groups. These findings persisted even after propensity score matching (PSM) adjustment. Notably, at a median follow-up of 32.5 months, TBI conditioning was not identified as an independent risk factor for OS, progression-free survival (PFS), cumulative incidence of relapse, or non-relapse mortality. Importantly, non-TBI regimens demonstrated non-inferior OS and PFS compared to TBI, even in high-risk subgroups, including those with multiple prior treatments, elevated prognostic scores, or aggressive histology. Our findings suggest that non-TBI conditioning regimens represent a viable alternative for PTCL patients undergoing allo-HSCT, potentially offering comparable efficacy with reduced toxicity. Larger-scale studies are warranted to validate these findings.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3459-3468"},"PeriodicalIF":2.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283884/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00277-025-06407-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a potentially curative treatment for peripheral T-cell lymphoma (PTCL), but the optimal conditioning regimen, particularly the use of total body irradiation (TBI), remains debated. To address this, we investigated outcomes from a cohort of 408 PTCL patients who underwent HSCT across five qualified medical centers in China. Focusing on a subset of 50 patients who received myeloablative conditioning prior to allo-HSCT, we compared outcomes between TBI-based (n = 28) and busulfan-based non-TBI (n = 22) regimens. Our analysis revealed comparable engraftment kinetics, incidence of acute and chronic graft-versus-host disease (GVHD), and overall survival (OS) between the TBI and non-TBI groups. These findings persisted even after propensity score matching (PSM) adjustment. Notably, at a median follow-up of 32.5 months, TBI conditioning was not identified as an independent risk factor for OS, progression-free survival (PFS), cumulative incidence of relapse, or non-relapse mortality. Importantly, non-TBI regimens demonstrated non-inferior OS and PFS compared to TBI, even in high-risk subgroups, including those with multiple prior treatments, elevated prognostic scores, or aggressive histology. Our findings suggest that non-TBI conditioning regimens represent a viable alternative for PTCL patients undergoing allo-HSCT, potentially offering comparable efficacy with reduced toxicity. Larger-scale studies are warranted to validate these findings.

外周血T细胞淋巴瘤患者全身照射(TBI)和非TBI调理方案在异基因造血干细胞移植中的比较:中国的一项多中心回顾性研究
同种异体造血干细胞移植(allo-HSCT)为外周t细胞淋巴瘤(PTCL)提供了一种潜在的治愈性治疗方法,但最佳调理方案,特别是全身照射(TBI)的使用仍存在争议。为了解决这个问题,我们调查了中国五家合格医疗中心408名接受HSCT的PTCL患者的队列结果。针对50例在同种异体造血干细胞移植前接受骨髓清除治疗的患者,我们比较了基于tbi (n = 28)和基于busulfan的非tbi (n = 22)方案的结果。我们的分析揭示了移植动力学、急性和慢性移植物抗宿主病(GVHD)的发生率以及TBI组和非TBI组之间的总生存期(OS)。这些发现在倾向得分匹配(PSM)调整后仍然存在。值得注意的是,在中位32.5个月的随访中,TBI状态未被确定为OS、无进展生存期(PFS)、累积复发发生率或非复发死亡率的独立危险因素。重要的是,与TBI相比,非TBI方案显示出非劣等的OS和PFS,即使是在高风险亚组中,包括那些多次治疗,预后评分升高或侵袭性组织学的患者。我们的研究结果表明,对于接受同种异体造血干细胞移植的PTCL患者来说,非tbi调节方案是一种可行的替代方案,可能提供相当的疗效和降低的毒性。有必要进行更大规模的研究来验证这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of Hematology
Annals of Hematology 医学-血液学
CiteScore
5.60
自引率
2.90%
发文量
304
审稿时长
2 months
期刊介绍: Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信